Conversation

BTAI a clinical-stage biopharma utilizing AI to identify improved therapies in neuroscience and immuno-oncology, announced that BXCL501, met primary and secondary endpoints of SERENITY I & SERENITY II, demonstrating robust treatment effect in the trials. Up 33 % premkt